Stands on 1 first-party reading of PubMed and ClinicalTrials.gov, not reporting.
Weight loss helps reduce atrial fibrillation in obese patients AI illustrationhow this picture was madeA randomized controlled trial comparing comprehensive weight loss intervention to usual care after atrial fibrillation catheter ablation in obese patients was published 4 November 2026. The trial appears in the journal Europace and is indexed on PubMed.[1]
The study, designated HOBIT-AF, enrolled 85 patients. Follow up ran for 15 months. The primary outcome measured was change in atrial fibrillation or atrial tachycardia burden, assessed via 14-day Holter monitoring at baseline and the final study visit.
Patients assigned to the active weight loss arm achieved a mean reduction of 6.8 to 7.0% of initial body weight. Metabolic parameters also improved in this group over the trial period.
The trial was funded by the Agency for Health Research and the Ministry of Health of the Czech Republic. One study author declared conflicts of interest including speaker panel roles for Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca and seven additional pharmaceutical and medical device manufacturers.
Proof1 source · 1 publisher · signed
What this stands on
"A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial." published in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular ele... as a randomized controlled trial (PubMed 42980655, doi 10.1093/europace/euag178). Sample: 85 as stated in the abstract. Duration: 15 month. Prim · PubMed and ClinicalTrials.gov, read by the New studies instrument · the fact record↗United Statesofficial source
Read directly from PubMed and ClinicalTrials.gov, the public registries of published studies and registered trials, not from anyone's report of it.
